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Abstract
Background: The aim of the present paper was to analyse cancer mortality in the Umbria region,
from 1978 to 2004. Mortality trends depend on a number of factors including exposures, health
system interventions, and possibly artefact (e.g. classification change, variations of data
completeness). Descriptive data on mortality only allow for generation of hypotheses to explain
observed trends. Some clues on the respective role of possible mortality determinants may be
found comparing mortality with incidence and survival data.
Methods: Mortality data for the periods 1978–1993 and 1994–2004 were supplied by the National
Institute of Statistics (ISTAT) and the Regional Causes of Death Registry (ReNCaM) respectively.
Sex and site-specific mortality time trends were analysed by the "joinpoint regression" method.
Results: For all sites combined, in both sexes, the standardised rate was first increasing before the
end of the eighties and decreasing thereafter. Gastric cancer mortality showed a different trend by
gender; that is the rate constantly decreased over the period among females while, for males, it was
first increasing up to 1985 and decreasing thereafter. Liver cancer trend showed a pattern similar
to gastric cancer. Large bowel cancer showed a gender specific trend, that is it was increasing
among males and stable among females. Also lung cancer mortality varied by gender: it started to
decline after 1989 among males but was steadily increasing over the study period among women.
A decreasing trend for female breast cancer mortality began in 1994. Prostate cancer mortality
trend is the only one showing two significant joinpoints: mortality decreased up to 1990, then it
increased up to 1998 and, finally, was decreasing.
Conclusion: Overall cancer mortality was decreasing in both sexes in Umbria and this favourable
trend will probably continue and further improve since population screening against breast, cervix,
and large bowel cancers were recently introduced. Besides gastric cancer, tobacco-related cancers
and prostate cancer mainly contributed to mortality reduction in males, whereas breast cancer
mainly contributed to declining mortality in females.
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Background
The analysis of mortality trends is an important tool to
monitor cancer control, and evaluate the outcomes of
modifications in population lifestyle, environmental
risks, and the effectiveness of health care [1]. Mortality
reduction remains the main objective of interventions
based on screening and treatment, and the ultimate indi-
cator to assess the effectiveness of most cancer control
strategies. Many reports showing significant changes in
cancer mortality are published in Italy and other countries
[2-4]. When other cancer burden indicators, like inci-
dence and population-based survival are considered
together with mortality, it is possible to discuss on the
effectiveness of public health strategies and find clues on
the respective role of different interventions. Trend based
surveillance may be of particular relevance when data are
available for geographic areas or population coinciding
with the target of specific interventions and with an
autonomous level of the health system.
Umbria is a small region in the centre of Italy (825,826
inhabitants at 2001 census). Regional health structures,
including two main oncology centres (Perugia and Terni),
are easy to reach by all residents Regional Population
screening interventions were introduced since 1998 for
the prevention of breast and cervical cancer [5,6]; moreo-
ver free offering of pap smear tests for cervix cancer pre-
ceded by many years population screening. Opportunistic
screening activities are likely to be diffused to some extent
for skin melanoma, prostate cancer, and large bowel can-
cer. Screening activities based on digital rectal examina-
tion first and later on PSA testing were present in Umbria
since the late eighties [7].
A regional cancer registry, the Umbrian Population Can-
cer Registry (RTUP), was established in the early '90 so
that data on incidence, prevalence and survival are availa-
ble for the period 1994–2002. The Registry also collects
regional mortality data from municipal offices and death
certificates, and is publishing yearly official general mor-
tality statistics, updated to the previous year.
The aim of the present paper is to analyse the cancer mor-
tality in the Umbria region, from 1978 to 2004. Possible
explanations of observed mortality trend will be proposed
with some focus on the period 1994–2004 and on the role
of health service interventions. Additional information to
interpret mortality trends will be derived by comparison
with incidence and survival data. Thus mortality will be
used as an indicator of cancer control future needs and
success of past interventions.
Methods
Mortality data were supplied by the National Institute of
Statistics (ISTAT) until 1993, while, for the following
1994–2004 period, they were supplied by the regional
Nominative Causes of Death Registry, ReNCaM, based on
the Registry population Offices of the Umbrian munici-
palities linked with the archives of death certificates col-
lected by the Local Health Districts and afterward utilised
by ISTAT. No major or systematic difference seems to exist
comparing ISTAT and ReNCaM based mortality data and,
since ReNCaM data are available earlier than ISTAT mor-
tality data, they allow the inclusion of more recent years
in the analysis [8].
ReNCaM data were not available before 1994. Causes of
death were classified according to the X International
Classification of Diseases [9]. Cancer sites examined are
listed in table 1. For each site we calculated the age-
adjusted mortality rates (AADR). Sex and site-specific
trends for standardized mortality rates were analysed by
"joinpoint regression" [10], using the SEER software [11].
The Umbria population (males + females, 1991 census)
was used as standard in the joinpoint analyses, aiming to
reduce the bias due to the exceeding difference in age
structure; the world standard population was used instead
for comparisons with national and international rates (it
was not used as the unique standard because it is very dif-
ferent from the aged population of the Region). Mortality
trend is approximated since it is described by straight seg-
ments but it is allowed to change during the study period
(i.e. segments have different slopes). The grid search
method allows the detection of segments best describing
data. A year when a change in trend is detected over the
study period is called a "joinpoint" and significant join-
points are retained in the final site specific models. The
maximum number of joinpoints allowed for each analysis
was three. The expected annual percent changes (EAPCs)
are reported to describe linear trends by period.
The unreported sites were disregarded because of variabil-
ity in mortality rates and low number of cases. The defini-
tion of head and neck cancer is not standard; we included
mouth, tongue, and pharynx sites (C01–C06, C10–C13)
and reported separately larynx cancer trend among males.
Uterus was considered as a single site, including cervix
(C53), corpus (C54) and undefined uterus (C55), since
the inaccuracy of death certifications (leading to the
assignment of C55 code) was not constant but decreasing
over the study period. Incidence (1994–2002) and sur-
vival (1994–98) data for Umbrian population were sup-
plied by the regional cancer registry RTUP [12,13].
Survival rates relative to 1978–1982 period, are referred to
incident cases resulting from an ad hoc survey carried out
in the eighties in the Umbria region [14].BMC Cancer 2007, 7:10 http://www.biomedcentral.com/1471-2407/7/10
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Results
Results of the joinpoint analyses by sex and cancer site,
applied to mortality rates spanning from year 1978 to
2004, are reported in table 1.
For all sites combined, both in males and females, a sig-
nificant joinpoint was found (figure 1); moreover the
trend shape was similar and the joinpoint year was very
close. In males standardised rates significantly increased
up to 1989 by 1.41% per year (95% CI from 0.45 to 2.39)
and significantly decreased thereafter by 1.10% (95% CI
from -1.61 to -0.58); among females the rate increased on
average of 1.09% (n.s.) each year till 1988 and afterward
decreased of 1.08% per year (p < 0.001).
Gastric cancer showed different mortality trends by gen-
der. It was constantly decreasing among females all over
the study period (EAPC = -2.79 P < 0.001) whereas in
Table 1: Joinpoint analysis by sex and cancer site in the Umbria region, 1978–2004*.
Site (ICD X) Sex Period EAPC 95% Confidence interval
All sites C00–C99 M 1978–1989 1.41 0.449 2.387
M 1989–2004 -1.10 -1.610 -0.581
F 1978–1988 1.09 -0.049 2.245
F 1988–2004 -1.08 -1.567 -0.584
Head and neck C01–
C06, C10–C13
M 1978–2004 -2.32 -3.368 -1.261
Oesophagus C15 M 1978–2004 -1.46 -2.653 -0.260
Stomach C16 M 1978–1985 1.55 -2.256 5.497
M 1985–2004 -3.29 -4.085 -2.482
F 1978–2004 -2.79 -3.193 -2.383
Colon-rectum C18–
C21
M 1978–2004 0.66 0.277 0.969
F 1978.2004 0.07 -0.622 0.758
Liver C22 M 1978–1991 5.14 2.175 8.181
M 1991–2004 -3.10 -5.342 -0.802
F 1978–2004 -1.75 -2.469 -1.028
Pancreas C25 M 1978–2004 0.27 -0.610 1.150
F 1978–2004 0.53 -0.311 1.384
Larynx C32 M 1978–2004 -3.02 -3.024 -2.413
Lung C33–C34 M 1978–1989 3.36 1.811 4.929
M 1989–2004 -1.22 -2.071 -0.364
F 1978–2004 2.38 1.718 3.055
Skin melanoma C43 M 1978–2004 3.13 1.153 5.138
F 1978–2004 2.64 0.841 4.463
Breast C50 F 1978–1994 0.93 -0.256 2.132
F 1994–2004 -1.72 -3.928 0.533
Uterus C53–C55 F 1978–2004 -3.27 -3.989 -2.553
Ovary C56 F 1978–1985 11.32 1.132 22.524
F 1985–2004 0.02 -1.574 1.647
Prostate C61 M 1978–1990 -1.41 -3.411 0.626
M 1990–1998 3.15 -0.794 7.249
M 1998–2004 -5.55 -9.764 -1.143
Bladder C67 M 1978–2004 0.33 -0.405 1.076
F 1978–2004 -1.04 -2.089 0.012
Brain C71 M 1978–2004 2.33 1.427 3.234
F 1978–2004 1.78 0.622 2.954
Hodgkin's disease C81 M 1978–2004 -4.96 -6.947 -2.918
F 1978–2004 -8.52 -15.980 -0.390
Lymphomas nH C83–
C85
M 1978–2004 2.63 1.220 4.066
F 1978–2004 2.38 0.815 3.976
Multiple myeloma C90 M 1978–2004 1.46 0.069 2.865
F 1978–2004 2.38 1.356 3.470
Leukaemias C91–C95 M 1978–2004 0.18 -0.178 1.112
F 1978–1981 22.35 0.333 49.197
F 1981–2004 -1.01 -1.830 -0.190
* Only significant joinpoints (p < .05) were retained in final models for each site.BMC Cancer 2007, 7:10 http://www.biomedcentral.com/1471-2407/7/10
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males it was slightly increasing up to 1985 and signifi-
cantly decreasing after the year 1985 (EAPC = -3.29, p <
0.02) (figure 1).
Similar trends by gender were found for liver cancer: in
females the rates decreased over all the period (EACP = -
1.75, p < 0.001); in males a significant joinpoint was
located in 1991, the curve was first steeply rising by 5.14%
per year and after decreasing by 1.75% per year, with
EACPs statistically significant in both periods.
Among males, head and neck, oesophagus, and larynx
cancers mortality was approximately linearly decreasing
over all study period and the slope was significant for all
the three sites; the very similar trend observed for the
above cancer sites is shown in figure 2.
A significant joinpoint was found for male lung cancer
mortality trend in the year 1989; mortality rates were
increasing until 1989 at an EACP of 3.36% and decreasing
thereafter at an EACP equal to 1.22%. Among women the
rates increased steadily over all study period with an EACP
equal to 2.38%. All the trends were statistically significant
(Fig. 1).
A joinpoint for female breast cancer mortality was
detected in 1994: however it is to note that, because of the
high variability in mortality rates, none of the slopes is sig-
nificant (Fig. 2).
Among female cancers, significant joinpoints were found
for ovary (Fig. 2) and leukaemias. In both cases, mortality
rates were sharply increasing (up to 1985 for ovary and to
1981 for leukaemias), and after remained constant or
decreased for ovary and leukaemias respectively. A line-
Observed standardized rates per 100.000 inhabitants (▲ males; ❍ females) and 'best' joinpoint model estimates (solid line  males; dashed line females) for selected cancer sites by gender Figure 1
Observed standardized rates per 100.000 inhabitants (▲ males; ❍ females) and 'best' joinpoint model estimates (solid line 
males; dashed line females) for selected cancer sites by gender.
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arly decreasing trend was observed for mortality from
uterine cancer on the whole (EACP = -3.27 p < 0.001).
Prostate cancer mortality trend is the only one showing
two significant joinpoints: mortality decreased up to
1990, then it increased up to 1998 and finally decreased
(Fig. 2). Only the last slope (EACP = -5.55) was statisti-
cally significant (p < 0.02).
Among the considered sites, no-significant trend was
revealed for colorectal cancer among females (males faced
a constant increase, EAPC = 0.66, p < 0.01) (Fig. 1), for
pancreatic and urinary bladder cancer in both sexes, and
for leukaemias in males. Finally, for the remaining study
sites a significant, approximately linear (i.e. without join-
points), trend was observed, increasing for melanoma,
brain cancer, non Hodgkin lymphomas and myeloma, in
both sexes, and decreasing for the other sites.
Discussion
The present analysis showed a trend toward mortality
reduction for many cancer sites. Both in males and in
females, a mortality reduction for all cancer sites com-
bined started from 1988–1989. The observed trend is in
agreement with national data [2] and data from other
countries [15,16]. In the US, mortality rates for all cancer
sites combined begun to decrease in 1992–93 [17].
Data from the regional Cancer Registry (1994–2002
period) show increasing incidence rates among females
that are mostly due to breast cancer but also to lung and
thyroid cancers. Among males a decreasing incidence
trend started in the middle nineties, when a decreasing
incidence trends for tobacco-related cancers became more
marked and also prostate screening activities decreased
after initial enthusiasms.
Observed standardized mortality rates per 100.000 inhabitants and 'best' joinpoint model estimates for female breast, ovary,  prostate, male head and neck (▲ observed; solid line joinpoint), oesophagus ( observed; dotted line joinpoint) and larynx  cancers ( observed; mixed line joinpoint) Figure 2
Observed standardized mortality rates per 100.000 inhabitants and 'best' joinpoint model estimates for female breast, ovary, 
prostate, male head and neck (▲ observed; solid line joinpoint), oesophagus ( observed; dotted line joinpoint) and larynx 
cancers ( observed; mixed line joinpoint).
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In a previous work, we found evidence for the diffusion of
prostate cancer screening in our region by comparing can-
cer registry's data with data from a population based sur-
vey covering the 1978–82 period, and estimated that as
many as 45% of the 1994 incident cases may be screen-
detected [18]. The opportunistic screening activity proba-
bly continued in the following years [7], so that the stand-
ardised (world population) incident rate increased
slightly from 38.9 to 43.8 per 100.000 inhabitants over
the period 1994–2002 (from 25.6 to 33.5 in the 0–74 age
group). Mortality rate decreased from 13.6 in 1999 to 9.3
in 2004, and five-year relative survival rate increased from
0.39 for 1978–1982 incident cases, to 0.76 for 1994–1998
incident cases. The prostate cancer opportunistic screen-
ing surely changed the meaning and interpretation of inci-
dence (reflecting screening intensity) and survival data.
The influence on mortality is less obvious. A peak in mor-
tality rates is uncommon (e.g. Italian mortality is simply
decreasing over the period 1988–1999) but is not unique
of Umbria [18]. Indeed it is present also in the US data
[17,18] and may be associated with changing diagnostic
activities since a pronounced increase in mortality
occurred earlier in US than in Umbria, and in that country
also screening diffusion occurred earlier. Attention
devoted to the disease may have influenced health profes-
sionals and cause of death coding or a true mortality
increase may have occurred. The decreasing mortality
trend after peaking may be partly, but not entirely, an arte-
fact due to changes in cause of death coding (i.e. mortality
is turning back to the pre-opportunistic screening levels),
and partly the consequence of the introduction of effec-
tive interventions. Thus mortality reduction may be the
result of new cancer treatments or of screening diffusion
or both [18,19]; evidence of efficacy for prostate cancer
screening, however, is yet inconclusive and also recent
studies yielded conflicting results [20-22]. It is also impor-
tant to note that, if we compare incidence rates as an indi-
cator of screening intensity, PSA screening diffusion in
Umbria seems lower than in many other Italian geo-
graphic areas covered by cancer registration; indeed highly
variable incidence rates among neighbouring Italian areas
probably reflect different screening activities [23].
Female breast cancer incidence increased from 66.0 to
83.8 (from 62.7 to 80.8 in the 0–74 age group) and mor-
tality diminished from 19.2 to 15.2 after 1994. The
screening, at first opportunistic, became organized for
females aged 50–69 starting from 1998–1999. Five-year
relative survival improved, for 1994–1998 incident cases,
to 86%, if compared to the 71% survival probability
reported for 1978–1982 cases. Treatment improvements
mostly contributed to mortality reduction because a
favourable trend appeared before the introduction of the
screening program; further improvements are expected as
a consequence of the screening introduction [24].
The joinpoint analysis relative to male lung cancer mortal-
ity indicates a decreasing slope after 1989. Really the rates
remained constant up to 1997 and after dramatically
decreased. This reduction parallel a decrease in male inci-
dence rates (incidence rate decreased from 42.9 in 1994 to
36.2 in 2004). The decline in incidence and mortality
rates was predicted many years ago considering the
decrease in the number of male smokers and the modifi-
cation in tar contents of cigarettes smoked [25]; the role of
tar content reduction on lung cancer risk, however, has
been questioned by more recent research [e.g. [26]].
Unfortunately, despite many efforts and resources
devoted, treatment progresses contributed little if any to
mortality reduction [2]: in Umbria one-year relative sur-
vival rate increased from 0.38 reported for 1978–1982
incident cases to 0.42 for 1994–1998 cases, and five-year
survival from 0.11 to 0.13. Lung cancer mortality trend in
females showed a constant increase in both mortality and
incidence, as in many other European countries, even if
some Authors suggest a more favourable trend in Euro-
pean young women over recent calendar years [27].
Over the twenty five years considered, colorectal cancers
mortality trend is slowly but significantly increasing in
males and stable in females. In Umbria large bowel cancer
incidence among males remained steady since 1994,
while among females decreased. Five-year survival rates
increased from 0.49 to 0.56 (1978–1982 and 1994–1998)
in men and from 0.54 to 0.57 in women. This relevant
improvement in survival, particularly in males, is likely to
be associated with treatment modification [28] rather
than with early diagnosis since population screening is
just starting in 2006 and opportunistic activities were not
very common.
The trend found for gastric cancer mortality is very com-
mon in developed countries. In the Umbria Region,
twenty five years ago, incidence and mortality rates were
very high [14]. The world population age-adjusted inci-
dence rates reached 32.3 per 100,000 inhabitants in males
and 16.4 in females. In the Northern areas of the Region,
such as in the neighbouring zones of the central Italy, the
male mortality rates were close to 50 (i.e. figures close to
those reported for Japan and Chile, the countries with the
highest mortality in the world).
In 2004 the adjusted mortality rate was 15.8 in men and
6.4 in women and the relative five-year survival increased
from 0.25 to 0.33 in males and from 0.28 to 0.32 in
females: that is probably due to decreasing prevalence of
Helicobacter pylori infection, changes in dietary habits [29].
A study carried out in a neighbouring area attributed an
increased gastric cancer risk to consumption of a "tradi-
tional" diet reach in red and conserved meat [29,30]; a dif-BMC Cancer 2007, 7:10 http://www.biomedcentral.com/1471-2407/7/10
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ferent attention to diet and health could explain the
earlier mortality decrease observed among females.
Head and neck, larynx, and oesophagus cancers arise from
close topographic areas, share similar histology [31], rec-
ognize common risk factors, though the relative impor-
tance may vary by site, and show very similar mortality
trends (Fig. 2b). All these sites showed a decrease which
varied from an EACP equal to -1.46 for oesophagus can-
cer, to -2.32 for head and neck, and -3.01 for larynx. The
incidence trends for these sites were quite the same. Sur-
vival rates instead show wide variation among sites [32].
The downward trend may depend perhaps on an earlier
stage at diagnosis and more probably on a lower exposure
to risk factors like alcohol consumption and tobacco
smoking [2].
Liver and pancreas mortality showed different trends. The
slopes relative to pancreatic cancer mortality resulted not
significant and rates presented a high variability. Inci-
dence rates resulted quite constant from 1994 in males,
and decreasing in females. Survival remained very low. An
improvement in diagnosis and classification likely
affected liver cancer trend [2]; even the joinpoint detected
in males, with an EAPC changing in 1991 from 5.14 to -
3.10, could be due to this change. As mortality, incidence
slowly decreased from first 1990s. Hepatitis B vaccination,
decreasing prevalence of HCV infection and some decline
in consumption of alcohol beverages may have contrib-
uted to the observed trend [2]; indeed, as pointed out
above, other alcohol related cancers showed a decreasing
mortality trend. The five-year relative survival, close to
zero for 1978–1982 cases, was about 10% for 1994–1998
cases. However, it is difficult to assess the role of treatment
improvement on survival for liver cancer [28].
All the same, the increasing trend in mortality for brain
cancer could be also related to improvement in diagnosis.
Both an improvement in diagnosis and registration, and
an increase in risk factors exposure may explain the rising
trend in mortality and incidence from melanoma of the
skin. Some Authors emphasized the relationship between
trends observed in different populations with respect to
the promotion of sun protection, level of education and
the surveillance of pigmented skin lesions [33,34]. Some
early diagnosis activities (e.g. melanoma day initiatives)
contributed, in Umbria, to an upward incidence and sur-
vival trend. However if compared to other Italian and
European areas, relative survival in our Region is rather
low, (0.64 at five-year).
The difficulty to consider separately the different uterus
sites when analysing mortality, hinders the interpretation
of trends. Clearly the diffusion of Pap smear testing for
cervix cancer may have led to some improvement in stage
at diagnosis but it mostly reduced cancer incidence, by
removing premalignant lesions before progression [5].
Both incidence and five-year relative survival rate for cer-
vix and corpus uteri cancers are quit stable. Relative sur-
vival for the 1994–1998 patients was 0.64 and 0.79
respectively for cervix and corpus uteri. The relatively low
survival from cervix cancer is based on few invasive can-
cers (about 40 per year), arising in somewhat older
women (i.e. they are probably more aggressive cancers
diagnosed in women non participating in pap screening)
[5]. Ovarian cancer mortality rates showed a very high var-
iability; an improvement in diagnostic definition of
abdominal cancers is likely to contribute to the increasing
trend observed from 1985 onward.
Joinpoint analysis of urinary bladder cancer evidenced a
decreasing trend that is non significant in males and sig-
nificant in females (EAPC -1.04). The changing criteria for
coding non-infiltrating urothelial carcinomas hamper the
possibility to evaluate incidence and survival trends [35];
to better analyse bladder cancer trends it would be neces-
sary to consider information about stage at diagnosis and
grading.
Different mortality trends were observed for Hodgkin's
(significant decrease in both sexes) and non-Hodgkin's
(significant increase) lymphomas. These differences are
clearly due to a different efficacy of available treatment
[13], even if changes in interpretations and classifications
of death certificates over time may have influenced results
[36]. Indeed five-year relative survival rate for Hodgkin's
disease, in our region, exceeded 85% while for non-Hodg-
kin's lymphomas the rate was close to 60%. Also inci-
dence trends varied by type and sex, and the regional
trends were similar to that reported for other Italian areas
[23].
The availability of more sensitive diagnostic tools and
more accurate reporting of diagnoses may have contrib-
uted to the observed increasing trends for more specified
sites or cancer types particularly when these trends were
paralleled by a decreasing trend for unspecified sites (e.g.
mortality for uterus cancer sites). So the raise of mortality
from multiple myeloma, in both sexes, may be a conse-
quence of an increased exposure to suspected carcinogens,
but also of an improvement in diagnosis; the surprising
trend reported for leukaemias, (i.e. non significant in
males, with a significant +22 EACP until 1981 and -1
thereafter in females) confirms the difficulty to under-
stand causes of death variations for some cancer sites.BMC Cancer 2007, 7:10 http://www.biomedcentral.com/1471-2407/7/10
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Conclusion
The analysis of mortality trend is an important tool to
monitor cancer control. In Umbria, mortality rates started
to decrease slowly but significantly in 1988–89 in both
sexes. Among males, declining mortality due to smoking-
related cancers and gastric cancer determined a favourable
trend. Among females, decreasing mortality seems mainly
due to the addition of a decreasing mortality for breast
cancer to the secular trend of gastric cancer. Thus, overall
mortality reduction is likely to depend on a mix of 'soci-
etal' changes (e.g. gastric cancer), preventive efforts (e.g.
liver cancer, tobacco-related cancers) and treatment
improvement (e.g. breast cancer). The recent introduction
of population-based screening interventions against cer-
vix, breast (1998) and colorectal (2006) cancers will prob-
ably contribute to reinforce the downward mortality
trends over the next years. Declining prostate cancer mor-
tality may be due to early diagnosis, treatment improve-
ment or both. Worrying trends, however, were apparent
for lung cancer among females and for other relatively
infrequent cancers.
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